Epizyme, Inc. has terminated its study of tazemetostat with enzalutamide or abiraterone/prednisone in participants with advanced prostate cancer (CELLO-1) due to a sponsor decision unrelated to safety concerns.
1 Discontinued Research Program
All entries for: Home
December 9, 2024
Epizyme
Discontinued Research
Boston, MA
51-200 employees
Disease Area: Multiple, Oncology, Rare Diseases
Drug Type: Small Molecule
November 15, 2024
Charles Rivers Laboratories
Layoffs
Wilmington, MA
10,001-50,000 employees
“One of Massachusetts’ major life science companies, Charles River Laboratories Inc., has revealed new details on its ongoing cost-savings initiatives, stating in an earnings call that it’s “already generating significant savings.”
The Wilmington-based company revealed a strategic turnaround plan in Q4 of 2023, announcing it would cut more than 6% of its workforce, and has continued to reduce staffing levels through Q3 of 2024, the Boston Business Journal reported.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
November 14, 2024
ApcinteX
Discontinued Research
United Kingdom
1-50 employees
A study on SerpinPC for patients with severe hemophilia A or moderately severe to severe hemophilia B was terminated due to a business and strategic decision.
1 Discontinued Research Program
Disease Area: Rare Diseases
Drug Type: Small Molecule
November 5, 2024
Asceneuron
Discontinued Drug
Lausanne, Switzerland
1-50 employees
Asceneuron, a small Swiss biotech, has terminated a mid-stage test of a new type of oral drug (ASN51) for people with Alzheimer’s disease citing strategic decisions, according to the federal clinical trials database.
1 Discontinued Drug: ASN51 (small molecule), O-GlcNAcase (OGA) inhibitor intended to curb the buildup of tau in patients with Alzheimer’s
Disease Area: Neurological Diseases
Drug Type: Small Molecule
October 31, 2024
Alnylam
Discontinued Drug, Discontinued Research
Cambridge, MA
1,001-5,000 employees
“Today announced the decision to suspend further clinical development of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase for the treatment of type 2 diabetes mellitus. This decision reflects portfolio prioritization efforts to allocate clinical, managerial and financial resources carefully to bring transformative medicines to patients.”
1 Discontinued Drug: ALN-KHK (biologic)
1 Discontinued Research Program
Disease Area: Chronic Disease
Drug Type: Biologic
October 29, 2024
Pfizer
Negative Outlook
New York, NY
50,001+ employees
Albert Bourla, chairman and chief executive officer:
“Clearly, IRA overall is negative for innovation and does not promote a spirit that people could provide investments, but there are also some good things about it. So clearly, I wouldn’t like to see that the out-of-pocket that next year will be $167 per month for all your medicines for seniors.
“That, we want to be maintained. But this forced price setting is not a negotiation and also the penalty deal between — are things that needs to change.”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
October 25, 2024
Sanofi
Negative Outlook
Paris, France
50,001+ employees
Brian Foard — Global Business Unit Head, Specialty Care:
“I think from an environment standpoint, the Inflation Reduction Act, there’s a couple of things in there. And as we’ve said before, our position is, it’s not really good for innovation just in general, the Inflation Reduction Act.”
Disease Area: Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
October 21, 2024
Takeda
Layoffs
Cambridge, MA
10,001-50,000 employees
“Takeda is laying off dozens of employees in Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) alert filed with the state late last week. The layoff process kicked off in late September and will run through March of next year, according to state records.
“While the WARN alert states that 79 employees across the two sites are set to face cuts, the final number “is not clear at this time” and will depend on potential “redeployment opportunities,” according to a detailed filing cited by Boston Business Journal.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
August 14, 2024
Evotec
Layoffs
Hamburg, Germany
1,001-5,000 employees
“Evotec is having to further shrink its manufacturing footprint and has identified 400 jobs globally that could potentially get cut, with a “sizable share” set to be laid off this year, according to Wojczewski. The first round of layoffs saw 100 workers cut across the UK and US, according to the company presentation. The rest of the layoffs will be made in Germany, Italy and France, Wojczewski added.
The company has also completed the shutdown of its chemistry work at a site in Lyon, France, and is closing an API manufacturing facility in Halle, Germany.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
August 2, 2024
Vir Biotechnology
Discontinued Research, Layoffs
San Francisco, CA
201-500 employees
“As part of its second-quarter business results, Vir revealed that it will no longer be continuing its work in COVID-19 and influenza, while pulling the plug on its T-cell-based viral vector platform. Instead, the biotech will restrict its virology business to its hepatitis B and D programs, allowing it to focus only on the “highest near-term value opportunities.”
“Under Vir’s strategic overhaul, the biotech will lay off 25% of its workforce, eliminating approximately 140 roles across its operations.”
“Vir now expects to close out the year with around 435 employees, which is some 200 employees fewer from its peak headcount in mid-2023.”
3 Discontinued Research Programs: COVID-19, influenza, and T-cell-based viral vector platform research programs.
Disease Area: Antiviral, Multiple, Oncology
Drug Type: Biologic, Small Molecule
